Drug intelligence / Profile preview

AIP 305

Development stage: Preclinical
Lead developer: AIP
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AIP 305 is a diagnostic radiopharmaceutical candidate being developed by Advanced Innovative Partners (AIP) for the imaging and detection of solid tumors. As a targeted imaging agent, it is designed to localize within tumor tissues to facilitate visualization via nuclear medicine techniques such as PET or SPECT. The program is currently in the IND-enabling phase, with the developer preparing for regulatory filings to transition into clinical trials. AIP 305 is part of a broader pipeline of radiopharmaceuticals that includes both diagnostic and therapeutic pairs (theranostics) for various oncology indications.

Beyond the preview

Go deeper on AIP 305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIP 305.

Explore the full profile